- Home
- TRVI vs GDO Comparison
TRVI vs GDO Comparison
Compare TRVI & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- GDO
- Stock Information
- Founded
- TRVI 2011
- GDO 2009
- Country
- TRVI United States
- GDO United States
- Employees
- TRVI N/A
- GDO N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- TRVI Health Care
- GDO Finance
- Exchange
- TRVI Nasdaq
- GDO Nasdaq
- Market Cap
- TRVI 211.4M
- GDO 182.8M
- IPO Year
- TRVI 2019
- GDO N/A
- Fundamental
- Price
- TRVI $2.75
- GDO $11.68
- Analyst Decision
- TRVI Strong Buy
- GDO
- Analyst Count
- TRVI 8
- GDO 0
- Target Price
- TRVI $9.13
- GDO N/A
- AVG Volume (30 Days)
- TRVI 659.5K
- GDO 39.4K
- Earning Date
- TRVI 11-06-2024
- GDO 01-01-0001
- Dividend Yield
- TRVI N/A
- GDO 9.81%
- EPS Growth
- TRVI N/A
- GDO N/A
- EPS
- TRVI N/A
- GDO N/A
- Revenue
- TRVI N/A
- GDO N/A
- Revenue This Year
- TRVI N/A
- GDO N/A
- Revenue Next Year
- TRVI N/A
- GDO N/A
- P/E Ratio
- TRVI N/A
- GDO N/A
- Revenue Growth
- TRVI N/A
- GDO N/A
- 52 Week Low
- TRVI $0.97
- GDO $11.21
- 52 Week High
- TRVI $4.00
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- TRVI 37.52
- GDO 28.18
- Support Level
- TRVI $2.80
- GDO $11.81
- Resistance Level
- TRVI $3.22
- GDO $11.99
- Average True Range (ATR)
- TRVI 0.20
- GDO 0.11
- MACD
- TRVI -0.03
- GDO 0.01
- Stochastic Oscillator
- TRVI 14.68
- GDO 5.88
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.